Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma Meeting Abstract


Authors: Vogl, D. T.; Younes, A.; Stewart, K.; Orford, K. W.; Bennett, M.; Siegel, D.; Berdeja, J. G.
Abstract Title: Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma
Meeting Title: 57th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 126
Issue: 23
Meeting Dates: 2015 Dec 5-8
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2015-12-03
Language: English
ACCESSION: WOS:000368020103254
PROVIDER: wos
Notes: Meeting Abstract: 3059 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos
MSK Authors
  1. Anas Younes
    203 Younes